Food and Drug Administration

•"It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations." -fda

•"violations may result in legal action without further notice, including, without limitation, seizure, and injunction in collaboration with other federal agencies. " -fda

 

Federal Trade Commission

•Monetary Fines

 

Banking and Financial

•Payment Processing

• underwriting assistance for CBD High-Risk applications

• Hot Media Topic

 

•Reputation & Legal Impact

• A step above your competitors

• Seal of compliance – confidence for your Costumer's

• Low annual cost vs the potential loss of business

     Over the past several years, the FDA has issued several warning letters to firms that market unapproved new drugs that allegedly contain cannabidiol (CBD). As part of these actions, the FDA has tested the chemical content of cannabinoid compounds in some of the products, and many were found to not contain the levels of CBD they claimed to contain. It is important to note that these products are not approved by the FDA for the diagnosis, cure, mitigation, treatment, or prevention of any disease. Consumers should beware purchasing and using any such products.

 

 

•2015 – 18 Warning Letters

•2016 – 22 Warning Letters

•2017 – 4 Warning Letters

•2018 – 1 Warning Letter

•2019 – 22 Warning Letters

​

​

 

​

•Underwriting assistance payment processing services 

•Website audit

•Social Media Scan

•Product reviews

• Product labeling guide

•Marketing post reviews

•Brick and Mortar stores

•Ecommerce business only

•Semi-Annual Compliance Risk assessment,

• FDA & FTC updates

• CBD industry updates

• Understanding COA in an unregulated lab testing market

 

•Take advantage of other CBD Service offerings with Nfinitech Solutions Corp